<DOC>
	<DOCNO>NCT02099474</DOCNO>
	<brief_summary>The purpose study assess evolution raltegravir concentration mother ( 3rd trimester pregnancy one month post-delivery ) neonate , drug use prevent mother-to-child HIV-1 transmission part combine antiretroviral regimen .</brief_summary>
	<brief_title>Evaluation Raltegravir During Third Trimester Pregnancy</brief_title>
	<detailed_description>1 . Objectives 1 . Principal objective - To study pharmacokinetic property raltegravir pregnant woman infect HIV-1 , third trimester pregnancy ( 30 37 week amenorrhea ) 1 month childbirth ( W4 W6 postpartum ) , well neonate . 2 . Secondary objective - Estimate frequency woman receive raltegravir indetectable viral load delivery ( strictly indetectable viral load , signal threshold technique use ) . - Describe tolerance raltegravir pregnant woman third trimester neonates 2 . Methodology - National multicenter pharmacokinetic study conduct among pregnant woman infect HIV-1 expose raltegravir pregnancy . 3 . Statistical method - Method population pharmacokinetic 5 sample : drug intake , 0.5 , 3 , 8 12 hour intake 2 visit ( 30 37 week amenorrhea , 4 6 week delivery ) .</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Pregnant woman , 30 37 week amenorrhea 18 year old Infected HIV1 Receiving therapeutic combination , stable least 15 day inclusion , raltegravir standard dose ( 400 mg twice daily ) doctor plan maintain till end pregnancy least one month delivery Informed consent sign mother investigator ( late day preinclusion examination conduct part research ) Affiliated person beneficiary social security system ( medical aid state AME social security system ) Participant agree registered national file people participate biomedical research Infected HIV2 Under 18 year old Receiving therapeutic association atazanavir ( Reyataz® ) , fosamprenavir ( Telzir® ) , efavirenz ( contain Sustiva® Atripla® ) Currently use medication , drug alcohol interfere research : rifampicine , phénobarbital , phénytoïne , topical gastrointestinal , antiacid adsorbent Presenting clinical situation acute pathology incompatible realisation pharmacokinetic study . Planned absence could hinder research participation ( travel abroad , move , imminent transfer ... ) Participating another research , except French perinatal survey ( ANRS CO1 EPF ANRS CO11 observatory ) , include exclusion period still progress preinclusion Person guardianship , deprive freedom judicial administrative decision</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV mother child prevention</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>